¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Non Aspirin Extended Release Oral"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • oral bacterium
    ÀÔ¼Ó±Õ
  • oral candidiasis
    ÀÔ¾ÈÄ­µð´ÙÁõ, ±¸°­Ä­µð´ÙÁõ
  • oral cavity
    ÀÔ¾È, ±¸°­
  • oral character
    ±¸°­±â¼º°Ý
  • oral cholecystography
    °æ±¸¾µ°³(ÁÖ¸Ó´Ï)Á¶¿µ(¼ú), °æ±¸´ã³¶Á¶¿µ(¼ú)
  • oral contraception
    °æ±¸ÇÇÀÓ(¹ý)
  • oral contraceptive
    °æ±¸ÇÇÀÓÁ¦, ¸Ô´ÂÇÇÀÓÁ¦
  • oral dependence
    ±¸°­ÀÇÁ¸
  • oral eroticism
    ±¸°­±â¼º¿å
  • oral fissure
    ÀÔ¼úÆ´»õ, ±¸°­¿­
  • oral floor
    ÀԾȹٴÚ
  • oral flora
    ÀԾȱչ«¸®, ±¸°­±ÕÁÖ
  • oral florid papillomatosis
    ÀԾȲÉÀ¯µÎÁ¾Áõ
  • oral focal hyperplasia
    ÀԾȱ¹¼Ò»óÇÇÁõ½Ä
  • oral glucose tolerance test
    °æ±¸Æ÷µµ´ç³»¼º°Ë»ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • oral contraception
    °æ±¸ÇÇÀÓ
  • oral contraceptive
    °æ±¸ÇÇÀÓÁ¦, ¸Ô´ÂÇÇÀÓÁ¦
  • oral dependence
    ±¸°­ÀÇÁ¸
  • oral disease
    ÀÔº´, ±¸°­Áúȯ
  • oral fissure
    ÀÔ¼úÆ´»õ
  • oral floor
    ÀԾȹٴÚ
  • oral flora
    ÀԾȱչ«¸®, ±¸°­±ÕÃÑ
  • oral microbial flora
    ÀԾȹ̻ý¹°¹«¸®
  • oral habit
    ÀÔ½À°ü, ±¸º®
  • oral health
    ±¸°­À§»ý
  • oral hygiene
    ±¸°­À§»ý
  • oral focal v hyperplasia
    ÀԾȱ¹¼Ò»óÇÇÁõ½Ä
  • oral immunization
    °æ±¸¸é¿ªÈ­
  • oral infection
    ÀԾȰ¨¿°, °æ±¸°¨¿°
  • oral inoculation
    °æ±¸Åõ¿©
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • non REM(= NREM) sleep
  • non communicating
    ºñ±³Å뼺
  • non compos mentis
    ½É½Å»ó½Ç»óÅÂ.
  • non enhanced image
    ºñÁ¶¿µ Áõ°­ ¿µ»ó
  • non hodgkin lymphoma
    ºñÈ£ÁöŲ¸²ÇÁÁ¾(¡­ðþ)
  • non inbred
    ºñ±ÙÄ£±³¹è°è µ¿¹° .
  • non proprietary name
    ÀϹݸí.
  • non radiator
    ¹æ»ç (¿¹¹æ,Ä¡¹æ)ºñ(¼±ÅÃ)¹æ»çü.
  • non respiratory
    ºñÈ£Èí(¼º)ÀÇ.
  • non respiratory acidosis
    ºñÈ£Èí¼º »êÁõ.
  • non respiratory alkalosis
    ºñÈ£Èí¼º ¾ËÄ«¸®Áõ.
  • non secretor
    ºñºÐºñÀÚ.
  • non stress test
    ºñ±äÀ强 °Ë»ç.
  • non-Hodgkins lymphoma
    ºñÈ£ÁöŲ¸²ÇÁÁ¾
  • non-competitive
    ºñ°æÇÕÀû<¼º>
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
OHI Occupational Health Institute; operative hypertension indicator; oral hygiene index; Oral Hygiene In...
AIA Aspirin Induced Asthma
ASA, A.S.A. Acetyl-Salicylic Acid(= Aspirin)
ACP accessory conduction pathway; acid phosphatase; acyl carrier protein; American College of Pathologis...
AIA allylisopropylacetamide; amylase inhibitor activity; anti-immunoglobulin antibody; anti-insulin anti...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
NANBH Non-A Non-B hepatitis
non-NMDA Non-N-Methyl-D-aspartate
NANC Non-adrenergic non-cholinergic
non-LTR Non-long terminal repeat
non-REM Non-rapid eye movement
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • non-nociceptive myelinated primary afferent
    ºñÄ§ÇØ ¼ö¿ë¼º ÀÏÂ÷ ±¸½É ¼¶À¯, ºñÀ¯ÇØ ¼ö¿ë¼º ÀÏÂ÷ ±¸½É ¼¶À¯
  • non-noxious cutaneous stimulation system
    ºñÀ¯Çؼº ÇǺΠÀڱذè
  • non-odontogenic
    ºñÄ¡¼º
  • non-opiate
    ºñ¾ÆÆí¼º
  • non-painful cutaneous stimulation system
    ºñÅëÁõ¼º Àڱذè
  • non-painful masticatory muscle hypertrophy
    ºñÅëÁõ¼º ÀúÀÛ±Ù ºñ´ë
  • non-patient
    ºñȯÀÚ
  • non-peptide transmitter
    ºñÆéƼµå Àü´Þ ¹°Áú
  • non-precious metal alloy base metal alloy
    ºñ±Í±Ý¼Ó ÇÕ±Ý
    Co-CrÀ̳ª Ni-Cr ÇÕ±Ý µî È­ÇÐÀûÀ¸·Î ºÒ¾ÈÁ¤ÇÑ
  • non-problematic TMJ clicking
    ¹®Á¦°¡ ¾ø´Â ÃøµÎÇϾǰüÀý ÀâÀ½
  • non-rebrething
    ºñÀçÈ£Èí
  • non-reducing
    ºñÁ¤º¹
  • non-reducing disc status
    ºñÁ¤º¹¼º °üÀý¿øÆÇ »óÅÂ
  • non-removable
    ºñÀ¯µ¿¼º
  • non-respiratory acidosis
    ºñÈ£Èí¼º »êÁõ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
acute non-lymphocytic leukaemia <haematology> A form of leukaemia which is characterised by the proliferation of immature bone marrow precursor cells in the marrow and immature white blood cells (granulocytes) in the bloodstream. Occurs primarily in adults and in infants under 1 year of age. Complications include abnormal bleeding and susceptibility to infections.
Symptoms include fatigue, weight loss, fevers, weakness, pallor, bone pains, bleeding gums, nosebleeds, easy bruising, enlarged lymph nodes and joint pains.
Trisomy-8 is the most common cytogenetic abnormality observed, followed by monosomy-7 and monosomy-5. Approximately 8% of cases show trisomy-8, mostly in AML (M1), AM (M4) and acute monocytic leukaemia (M5). Many pre-leukaemic conditions, acute non-lymphocytic leukaemia and secondary leukemia show monosomy-7 or deletion of the long arm of chromosome 7.
Treatment includes chemotherapy and/or bone marrow transplant.
Acronym: ANLL
Incidence: 2.5 cases per 100,000 (all ages).
Origin: Gr. Haima = blood
(07 Apr 1998)
analgesics, non-narcotic Drugs that have principally analgesic, antipyretic, and anti-inflammatory actions. They do not bind to opioid receptors and are not classified under the controlled substances act.
(12 Dec 1998)
anti-inflammatory agent, non-steroidal Anti-inflammatory agents that are not steroids. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They are used primarily in the treatment of chronic arthritic conditions and certain soft tissue disorders associated with pain and inflammation. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. Certain nsaids also may inhibit lipoxygenase enzymes or phospholipase c or may modulate T-cell function. (ama drug evaluations annual, 1994, p 1814-5)
(12 Dec 1998)
auctorum non Not of authors.
(09 Jan 1998)
cancer, lymphoma, non-hodgkin's A lymphoma is a cancer that develops in the lymphatic system. The most common symptom of non-Hodgkin's lymphomas is a painless swelling in the lymph nodes in the neck, underarm, or groin. Non-Hodgkin's lymphomas are diagnosed with a biopsy of an enlarged lymph node. Follow-up examinations are important after lymphoma treatment. Most relapses occur in the first 2 years after therapy.
(12 Dec 1998)
carcinoma, non-small-cell lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. They are dealt with collectively because of the shared properties of poor response to conventional chemotherapy and the potential for cure with surgical resection in a fraction of patients.
(12 Dec 1998)
Gomori's non-specific acid phosphatase stain <technique> A method in which formalin-fixed frozen sections are incubated in a substrate containing sodium beta-glycerophosphate and lead nitrate at pH 5.0; the insoluble lead phosphate produced is treated with ammonium sulfide to give a black lead sulfide.
(05 Mar 2000)
Gomori's non-specific alkaline phosphatase stain <technique> A calcium-cobalt sulfide method using frozen sections or cold acetone-or formalin-fixed paraffin sections, plus sodium beta-glycerophosphate as a substrate at pH 9.0 to 9.5 with Mg++ as activator; calcium ions precipitate the liberated phosphate, cobalt salt replaces the calcium phosphate, and ammonium sulfide converts the product to a black cobalt sulfide.
(05 Mar 2000)
chromosomal proteins, non-histone Nucleoproteins which in contrast to histones are acid insoluble. They are involved in chromosomal functions; e.g. They bind selectively to DNA, stimulate transcription resulting in tissue-specific RNA synthesis and undergo specific changes in response to various hormones or phytomitogens.
(12 Dec 1998)
prescriptions, non-drug Written directions for the preparation, administration, or application of a non-drug remedy. This includes prescriptions for corrective lenses, self-help and orthopedic devices, and physical therapy and rehabilitation measures.
(12 Dec 1998)
cytosol non-specific dipeptidase <enzyme> Also referred to as peptidase a (see synonym to penicillopepsin, EC 3.4.23.20)
Registry number: EC 3.4.13.-
Synonym: glycyl-l-leucine hydrolase, glycylleucine dipeptidase, gly-leu dipeptide peptidase, dipeptide hydrolase, glycyl-leucine dipeptidase
(26 Jun 1999)
histiocytosis, non-langerhans-cell Group of disorders which feature accumulations of active histiocytes and lymphocytes, but where the histiocytes are not langerhans cells. The group includes haemophagocytic lymphohistiocytosis, infection-associated haemophagocytic syndrome, sinus histiocytosis, xanthogranuloma, reticulohistiocytoma, juvenile xanthoma, xanthoma disseminatum, as well as the lipid storage diseases (sea-blue histiocyte syndrome and niemann-pick disease).
(12 Dec 1998)
nodular non-X histiocytosis A rare recurring generalised eruption in adults of flesh coloured or erythematous papules remaining localised to the skin and consisting of dermal nodules of mononuclear histiocytes that do not stain for lipid.
Synonym: nodular non-X histiocytosis.
(05 Mar 2000)
non-arcon articulator An articulator with the equivalent condylar guides attached to the lower member and the hinge axis to the upper member.
(05 Mar 2000)
non compos mentis Not of sound mind; mentally incapable of managing one's affairs.
Origin: L. Non, not, + compos, participating, competent, + mens, gen. Mentis, mind
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • non obstante
    ..¿¡µµ ºÒ±¸Çϰí
  • non placet
    (±³È¸,´ëÇÐÀÇ Áýȸ¿¡¼­)ÀÌÀÇ;¹Ý´ëÅõÇ¥
  • non plus ultra
    NE PLUS ULTRA
  • non possumus
    ¹«´É·Â(ºÒ´É)ÀÇ ½Åû
  • non prosequitur
    (¼Ò¼ÛÀýÂ÷¸¦ Ÿ¸È÷ ÇÏ´Â ¿ø°í¿¡ ´ëÇÑ)ÆÐ¼ÒÆÇ°á
  • non seq.
    non sequitur
  • non sequitur
    ±×¸©µÈ °á·Ð
  • non troppo
    Áö³ªÄ¡Áö ¾Ê°Ô;¾Ë¸Â°Ô
  • non-
    ¾Ê´Ù;¾Æ´Ï´Ù
  • non-
    (ÀÚÀ¯·ÎÀÌ ¸í»ç,Çü¿ë»ç,ºÎ»ç¿¡ ºÙ¿©¼­);ºñ;ºÒ;¹«ÀÇ ¶æÀ» ³ªÅ¸³¿
  • sine qua non
    ÇÊ¿ä Á¶°Ç
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á